Evidence map›Paper›PMID 29904298›Full record

ArticleProceedings (Baylor University. Medical Center)2018

Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.

Laurie Jansky, Pallavi Mukkamala, Deborah Jebakumar, Arundhati Rao, Tove M Goldson, Samuel N Forjuoh

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Anticoagulant-Related Nephropathy.Journal of the American Society of Nephrology : JASN · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laurie JanskyDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas.
Pallavi MukkamalaDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas.
Deborah JebakumarDepartment of Pathology, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas.
Arundhati RaoDepartment of Pathology, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas.
Tove M GoldsonDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas.
Samuel N ForjuohDepartment of Family and Community Medicine, Baylor Scott & White Health and College of Medicine, Texas A&M Health Science Center, Temple, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dabigatran, a new oral anticoagulant, is a direct thrombin inhibitor used as an alternative to warfarin to reduce the risk of stroke and systemic embolism with nonvalvular atrial fibrillation. We report a case of a man who resumed dabigatran after 6 weeks of prior therapy and began experiencing hematuria with worsening kidney function. Renal biopsy with immunofluorescence and electron microscopy showed mesangial deposits consistent with immunoglobulin A nephropathy. With discontinuation of dabigatran and addition of methylprednisolone, the gross hematuria cleared and urine output improved.

Indexed as

Acute kidney injurydabigatranhematuriaimmunoglobulin A nephropathy

Identifiers

PMID29904298
PMCPMC5997039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.